Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Begins Global KRN23 PIII for Pediatric X-Linked Hypophosphatemia
October 28, 2016
- Sumitomo Dainippon’s Half-Year Revenue Dips on Price Cut, Currency
October 28, 2016
- Sumitomo Dainippon to Venture into Authorized Generic Arena
October 28, 2016
- Public “IP Platforms” Necessary for Startups: IPSN President
October 28, 2016
- Daiichi Sankyo Gets US Commercialization Rights on 2 Abuse-Deterrent Opioids
October 27, 2016
- Patritumab Joins I-SPY 2 Breast Cancer Program in US: Daiichi Sankyo
October 27, 2016
- Switching Over to Biologics Should Be Considered at Early Stage in Serious Cases of Psoriasis: Dermatologist
October 27, 2016
- AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
October 26, 2016
- Wholesalers Hails Gilead Ambition to Unearth More Hep C Patients through Collaboration
October 26, 2016
- Mitsubishi Tanabe Lifts Earnings Outlook on Simponi, Vaccines
October 26, 2016
- Prof. Yamanaka Eager to Bridge Valley of Death through Takeda Collaboration
October 25, 2016
- Astellas Wins Xtandi Label Update in US for PFS Extension
October 25, 2016
- Sunovion Completes Acquisition of Cynapsus
October 25, 2016
- Shionogi Ups Earnings Forecast for April-September
October 25, 2016
- Ono Files Patent Infringement Suit over Keytruda
October 25, 2016
- Nihon Generic Takes Over 3 Brands from MSD
October 24, 2016
- Prasugrel Disappoints in PIII Study for Ischemic Cerebrovascular Disease
October 24, 2016
- 295 Staffers Applied for Voluntary Redundancy: Sumitomo Dainippon
October 24, 2016
- Daiichi Sankyo Stops Patient Enrollment for Pexidartinib PIII, but Continues Study
October 24, 2016
- Oncolys, DNA Chip Research Team Up to Study Potential of TelomeScan as Companion Diagnostic for CRPC
October 24, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…